Drug Type Small molecule drug |
Synonyms Befiradol + [1] |
Target |
Mechanism 5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Molecular FormulaC20H22ClF2N3O |
InChIKeyPKZXLMVXBZICTF-UHFFFAOYSA-N |
CAS Registry208110-64-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Befiradol Fumarate | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Neuropathies | Phase 2 | - | - | |
Cancer Pain | Phase 1 | HU | - | |
Cancer Pain | Phase 1 | FR | - | |
Neuralgia | Phase 1 | HU | - | |
Neuralgia | Phase 1 | BE | - | |
Neuralgia | Phase 1 | ES | - | |
Neuralgia | Phase 1 | FR | - | |
Neuralgia | Phase 1 | IT | - | |
Neuralgia | Phase 1 | NL | - | |
Neuralgia | Phase 1 | FI | - |
Phase 2 | 27 | (NLX-112) | fidpixazik(sbjltrmdhc) = tilyxqress ogewjekzzx (laxlmznuzy, zcyvztevgv - mkpsloxttu) View more | - | 23 Apr 2024 | ||
Placebo (Placebo) | fidpixazik(sbjltrmdhc) = phmlujvfni ogewjekzzx (laxlmznuzy, vadfvanujl - poubadvkjc) View more |